FREDUNPharmaceuticals
Fredun Pharmaceuticals Ltd — Profit & Loss Statement
₹1671.80
-1.27%
Fredun Pharmaceuticals Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | -42657.04 | 0.02 Cr | -0.30 Cr | — |
| Tax Rate For Calcs | 0.28 | 0.27 | 0.38 | 0.26 | — |
| Normalized EBITDA | 54.91 Cr | 37.78 Cr | 27.81 Cr | 16.30 Cr | — |
| Total Unusual Items | 0.00 | -0.02 Cr | 0.07 Cr | -1.15 Cr | — |
| Total Unusual Items Excluding Goodwill | 0.00 | -0.02 Cr | 0.07 Cr | -1.15 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 19.74 Cr | 15.62 Cr | 10.81 Cr | 6.34 Cr | — |
| Reconciled Depreciation | 5.04 Cr | 3.80 Cr | 2.81 Cr | 2.16 Cr | — |
| Reconciled Cost Of Revenue | 347.59 Cr | 274.94 Cr | 218.27 Cr | 184.26 Cr | — |
| EBITDA | 54.91 Cr | 37.77 Cr | 27.88 Cr | 15.15 Cr | — |
| EBIT | 49.87 Cr | 33.97 Cr | 25.07 Cr | 12.99 Cr | — |
| Net Interest Income | -22.38 Cr | -13.64 Cr | -9.26 Cr | -4.70 Cr | — |
| Interest Expense | 22.38 Cr | 12.52 Cr | 7.56 Cr | 4.39 Cr | — |
| Normalized Income | 19.74 Cr | 15.63 Cr | 10.77 Cr | 7.18 Cr | — |
| Net Income From Continuing And Discontinued Operation | 19.74 Cr | 15.62 Cr | 10.81 Cr | 6.34 Cr | — |
| Total Expenses | 404.29 Cr | 312.37 Cr | 249.35 Cr | 208.88 Cr | — |
| Diluted Average Shares | 0.44 Cr | 0.47 Cr | 0.47 Cr | 0.42 Cr | — |
| Basic Average Shares | 0.44 Cr | 0.46 Cr | 0.45 Cr | 0.42 Cr | — |
| Diluted EPS | 44.83 | 33.32 | 22.93 | 15.26 | — |
| Basic EPS | 44.83 | 33.66 | 24.13 | 15.26 | — |
| Diluted NI Availto Com Stockholders | 19.74 Cr | 15.62 Cr | 10.81 Cr | 6.34 Cr | — |
| Net Income Common Stockholders | 19.74 Cr | 15.62 Cr | 10.81 Cr | 6.34 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 19.74 Cr | 15.62 Cr | 10.81 Cr | 6.34 Cr | — |
| Net Income Including Noncontrolling Interests | 19.74 Cr | 15.62 Cr | 10.81 Cr | 6.34 Cr | — |
| Net Income Discontinuous Operations | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income Continuous Operations | 19.74 Cr | 15.62 Cr | 10.81 Cr | 6.34 Cr | — |
| Tax Provision | 7.75 Cr | 5.83 Cr | 6.70 Cr | 2.26 Cr | — |
| Pretax Income | 27.49 Cr | 21.45 Cr | 17.51 Cr | 8.60 Cr | — |
| Other Non Operating Income Expenses | 2.45 Cr | 0.18 Cr | 0.32 Cr | 0.41 Cr | — |
| Special Income Charges | 0.00 | -0.02 Cr | 0.07 Cr | -1.15 Cr | — |
| Net Non Operating Interest Income Expense | -22.38 Cr | -13.64 Cr | -9.26 Cr | -4.70 Cr | — |
| Interest Expense Non Operating | 22.38 Cr | 12.52 Cr | 7.56 Cr | 4.39 Cr | — |
| Operating Income | 47.42 Cr | 34.20 Cr | 24.99 Cr | 12.86 Cr | — |
| Operating Expense | 56.70 Cr | 37.43 Cr | 31.08 Cr | 24.62 Cr | — |
| Other Operating Expenses | 31.35 Cr | 9.98 Cr | 8.27 Cr | 5.50 Cr | — |
| Depreciation And Amortization In Income Statement | 5.04 Cr | 3.80 Cr | 2.81 Cr | 2.16 Cr | — |
| Depreciation Income Statement | 5.04 Cr | 3.80 Cr | 2.81 Cr | 2.16 Cr | — |
| Selling General And Administration | 0.19 Cr | 8.58 Cr | 5.92 Cr | 6.84 Cr | — |
| General And Administrative Expense | 0.19 Cr | 5.30 Cr | 3.27 Cr | 2.12 Cr | — |
| Gross Profit | 104.12 Cr | 71.64 Cr | 56.07 Cr | 37.48 Cr | — |
| Cost Of Revenue | 347.59 Cr | 274.94 Cr | 218.27 Cr | 184.26 Cr | — |
| Total Revenue | 451.71 Cr | 346.58 Cr | 274.34 Cr | 221.74 Cr | — |
| Operating Revenue | 451.71 Cr | 346.58 Cr | 274.34 Cr | 221.74 Cr | — |
| Interest Income | — | 0.01 Cr | 0.02 Cr | 0.04 Cr | 0.02 Cr |
| Rent Expense Supplemental | — | 4.13 Cr | 2.86 Cr | 2.17 Cr | 1.50 Cr |
| Write Off | — | 0.02 Cr | 0.03 Cr | 0.39 Cr | 0.00 |
| Total Other Finance Cost | — | 1.13 Cr | 1.72 Cr | 0.35 Cr | 0.32 Cr |
| Interest Income Non Operating | — | 0.01 Cr | 0.02 Cr | 0.04 Cr | 0.02 Cr |
| Selling And Marketing Expense | — | 3.29 Cr | 2.64 Cr | 4.72 Cr | 1.88 Cr |
| Rent And Landing Fees | — | 4.13 Cr | 2.86 Cr | 2.17 Cr | 1.50 Cr |
| Other Special Charges | — | — | -0.09 Cr | 0.77 Cr | 1.33 Cr |
| Research And Development | — | — | 67000.00 | 85000.00 | 0.03 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Fredun Pharmaceuticals Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.